Arrien Pharmaceuticals Receives $2,000,000 Series A Funding Round

  • Feed Type
  • Date
    9/12/2011
  • Company Name
    Arrien Pharmaceuticals
  • Mailing Address
    121 Wakelee Avenue Ansonia, CT 06401
  • Company Description
    Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting cell signaling pathways – A target class in treating neurodegenerative, Cancer, Inflammatory and Metabolic diseases.
  • Website
    http://www.arrienpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $2,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Arrien has identified an active First-in-Class ARN-1032 and ARN-3016 which are potent inhibitors of protein kinases and demonstrated potent anticancer activities in a variety of cancer cell lines. Currently Arrien is conducting lead optimization process and early PK studies.
  • M&A Terms
  • Venture Investor
    Undisclosed